Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

 
• By Joseph Haas
Cancer cell therapy
Sanofi will call on Scribe's gene-editing expertise for its NK cancer cell therapy efforts • Source: Shutterstock

More from Deals

More from Business